Mitovaryn BPC-157 Learning Center
BPC-157 for Stomach Ulcers and GI Support: What the Evidence Shows
A careful look at stomach-ulcer claims, animal GI research, the limited ulcerative-colitis evidence, oral bioavailability, safety, and the established diagnostic and treatment pathways that should not be replaced by an experimental peptide.
BPC-157 has been studied in animal models of gastrointestinal injury, but there is no adequate human evidence showing that it heals stomach or duodenal ulcers. FDA’s 2026 review evaluated BPC-157 for ulcerative colitis—a different disease—and concluded that the available data did not support its use. BPC-157 is not an FDA-approved ulcer or GI treatment.
“GI support” can blur very different conditions
A stomach ulcer is not a general synonym for indigestion, intestinal permeability, irritable bowel syndrome, inflammatory bowel disease, or food sensitivity. Each has a different definition, diagnostic pathway, risk profile, and evidence base. A meaningful review must ask what condition was actually studied, in which species, by which route, and with what clinical outcome.
| Condition or claim | What it means | BPC-157 evidence status |
|---|---|---|
| Gastric or duodenal ulcer | An open sore in the stomach or first part of the small intestine; common causes include H. pylori and NSAIDs. | No established human benefit |
| Ulcerative colitis | A chronic inflammatory disease causing inflammation and ulcers in the large intestine—not a stomach ulcer. | One small exploratory enema trial |
| Crohn’s or celiac disease | Distinct immune-mediated diseases requiring condition-specific evaluation and care. | No clinical studies identified by FDA |
| IBS or functional dyspepsia | Symptom-based disorders that do not mean an ulcer is present. | No validated treatment role |
| “Leaky gut” or general gut repair | A broad marketing label that may refer to intestinal-permeability research but is not a substitute for a diagnosis. | No proven clinical outcome |
The word “ulcer” creates a common mix-up. Ulcerative colitis affects the colon. A gastric ulcer affects the stomach, and a duodenal ulcer affects the duodenum. Evidence from one location or disease cannot be transferred automatically to another.
Why BPC-157 became associated with the gut
BPC-157 is a synthetic 15-amino-acid peptide described as a fragment of a larger body-protection compound originally isolated from human gastric juice. That origin story does not show that a commercial BPC-157 product is a naturally occurring human supplement, nor does it establish that swallowing it repairs the stomach lining. The BPC-157 overview explains the terminology and chemical-form problem in more detail.
Animal injury models generated the hypothesis
Preclinical studies have explored BPC-157 in rodents exposed to experimentally induced GI injury, including lesions created by medications, chemicals, ischemia, or other challenges. Researchers have reported signals involving mucosal injury, inflammation, vascular responses, nitric-oxide pathways, and tissue repair. These experiments help form hypotheses; they do not establish that BPC-157 treats naturally occurring human peptic-ulcer disease.
Animal studies can differ from clinical care in dose, route, timing, injury model, anatomy, metabolism, endpoints, and product identity. An improvement in a rat lesion score is not the same result as confirmed ulcer healing on human endoscopy, eradication of H. pylori, prevention of bleeding, or reduced recurrence.
Mechanism language is not an outcome
Claims about angiogenesis, tight junctions, cytoprotection, cell migration, or inflammatory signaling are often presented as though they prove “gut repair.” FDA’s 2026 review said molecular targets had not been identified and mechanisms remained poorly understood. Read the mechanisms guide to distinguish a proposed pathway from a demonstrated patient benefit.
No human stomach-ulcer timeline has been established. Claims that symptoms improve in days or ulcers heal within a fixed number of weeks are not validated BPC-157 treatment expectations. Feeling better also does not confirm that an ulcer has healed or that its cause has been treated.
What FDA’s 2026 BPC-157 review actually found
FDA evaluated BPC-157 free base and BPC-157 acetate for proposed compounded use in ulcerative colitis. The agency did not evaluate stomach ulcers as the nominated condition. It also declined to evaluate proposed Crohn’s and celiac uses because the nominations lacked sufficient information, and FDA did not identify clinical studies using BPC-157 in those populations.
| FDA finding | What it means for GI claims |
|---|---|
| A single small ulcerative-colitis trial was available as a meeting abstract. | Important design and analysis details were missing, and FDA called the data inadequate to support efficacy or safety. |
| The investigated UC product was administered by rectal enema for two weeks. | It does not establish that an oral capsule treats UC, reaches the same tissue, or treats a stomach ulcer. |
| No oral, subcutaneous, nasal, or transdermal BPC-157 studies were identified in people with UC. | Common marketed routes lack condition-specific human clinical evidence. |
| No human pharmacokinetic data were found for oral, subcutaneous, nasal, or transdermal administration. | Absorption, exposure, dose-response, and route-comparison claims remain unestablished. |
| Clinical safety information was insufficient. | Small, short studies with limited monitoring cannot define a reliable adverse-effect profile or long-term safety. |
| Neither form is a component of an FDA-approved drug. | BPC-157 has no FDA-approved indication, dose, route, cycle, or ulcer-treatment protocol. |
FDA’s conclusion was that available data did not support using BPC-157 for ulcerative colitis and that the balance of characterization, effectiveness, and safety information weighed against adding the reviewed forms to the Section 503A Bulks List. This was a compounding-policy evaluation, not an approval of BPC-157 for another GI use. See the broader research summary and BPC-157 FAQ.
What evidence-based stomach-ulcer care targets
Peptic-ulcer care is built around confirming the problem, identifying the cause, healing the sore, and preventing complications or recurrence. According to the National Institute of Diabetes and Digestive and Kidney Diseases, the two most common causes are Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs such as aspirin, ibuprofen, and naproxen.
Confirm the diagnosis
Symptoms alone cannot prove an ulcer. Depending on the situation, clinicians may use H. pylori testing, upper-GI endoscopy, biopsy, blood tests, or imaging.
Treat the cause
H. pylori generally requires a prescribed multi-drug eradication regimen. NSAID-associated ulcers may require clinician-directed medication changes and protective therapy.
Verify healing when needed
Follow-up can include confirmation that H. pylori was eradicated or repeat evaluation for a persistent, recurrent, complicated, or concerning ulcer.
Common medical approaches include proton-pump inhibitors, H2 blockers, antibiotics for confirmed H. pylori, and endoscopic or hospital treatment for complications. This does not mean every person receives the same regimen. Antibiotic resistance, medication history, allergies, ulcer location, bleeding risk, age, and other findings can change the plan.
Do not stop an NSAID, aspirin, anticoagulant, antiplatelet medicine, acid-suppressing drug, antibiotic, or other prescribed treatment based on a supplement article. The clinician who knows why the medicine was prescribed must weigh the risks of continuing, changing, or stopping it.
Seek urgent medical care for possible ulcer complications: black or tarry stool; red or maroon blood in stool; vomiting blood or material that looks like coffee grounds; sudden severe abdominal pain that does not go away; dizziness, fainting, rapid pulse, or other signs of shock; or a marked worsening of symptoms.
Oral BPC-157, dosing, interactions, and product quality
“Direct contact with the stomach” is not proof of bioavailability
An oral capsule passes through the GI tract, but location alone does not establish stability, absorption, tissue exposure, receptor engagement, or clinical effect. FDA found no human oral pharmacokinetic data. It also found a registered oral phase 1 study with no posted results and no associated published study located during the agency’s review.
There is no approved GI dose or cycle
No FDA-approved dose, frequency, weight-based calculation, treatment duration, taper, or maintenance schedule exists for BPC-157. Protocols promoted for “mild ulcers,” “intensive healing,” or “gut restoration” are not validated prescribing standards. The absence of an approved dose also prevents a reliable benefit-risk comparison.
Interactions are not adequately characterized
There is no established evidence that BPC-157 can be safely combined with PPIs, H2 blockers, antibiotics, bismuth, NSAIDs, anticoagulants, antiplatelet drugs, corticosteroids, biologics, immunomodulators, or other GI treatments. “No known interaction” can mean that the combination has not been studied—not that compatibility has been proven.
Purity does not answer the medical question
A lot-specific certificate and appropriate analytical testing can help answer identity, assay, purity, impurity, microbial-quality, and stability questions. They cannot establish that an ulcer is present, that a product treats it, that oral absorption is adequate, or that the product is FDA approved. FDA also highlighted inconsistent naming of free-base and acetate forms, peptide impurities, aggregation, and immunogenicity concerns. Use the peptide-purity checklist and Mitovaryn’s testing information to evaluate documentation in the correct context.
Regulatory status also varies by product, activity, and jurisdiction. The peptide legality guide explains why a “research use only” label, prescription, or certificate of analysis does not independently settle whether a product may be marketed or used as a human treatment.
BPC-157 and GI health: common questions
Does BPC-157 heal stomach ulcers?
No adequate human evidence shows that BPC-157 heals gastric or duodenal ulcers. The interest comes mainly from animal models of induced GI injury, which cannot establish effectiveness in human peptic-ulcer disease.
Have human trials tested BPC-157 for stomach ulcers?
FDA’s 2026 review did not identify a human clinical trial establishing BPC-157 as a stomach-ulcer treatment. The limited GI trial discussed by FDA involved rectal-enema administration for ulcerative colitis, not oral treatment of gastric or duodenal ulcers.
Is BPC-157 FDA approved for ulcers or GI conditions?
No. Neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug. There is no FDA-approved GI indication, dose, route, treatment cycle, or maintenance protocol.
Does BPC-157 treat H. pylori infection?
There is no clinical evidence that BPC-157 eradicates H. pylori. Confirmed infection is treated with a clinician-selected combination regimen, commonly involving antibiotics and acid suppression, followed by appropriate confirmation of eradication.
Is ulcerative-colitis research evidence for stomach-ulcer treatment?
No. Ulcerative colitis affects the large intestine, while gastric and duodenal ulcers occur in the upper GI tract. FDA considered the small exploratory UC enema study inadequate to support efficacy or safety, and it cannot validate a different disease, route, or formulation.
Can BPC-157 treat Crohn’s disease, celiac disease, IBS, or “leaky gut”?
No treatment role has been established for these distinct conditions. FDA did not identify clinical studies in Crohn’s or celiac populations during its 2026 review. IBS and broad “leaky gut” claims should not be treated as interchangeable with inflammatory bowel disease or a confirmed ulcer.
Is oral BPC-157 proven to be bioavailable?
No. FDA found no human pharmacokinetic data after oral administration. A capsule reaching the stomach does not prove meaningful absorption, tissue exposure, dose-response, or a clinical effect.
What is the correct BPC-157 dose for GI support?
There is no FDA-approved BPC-157 dose for stomach ulcers, ulcerative colitis, IBS, intestinal permeability, or general GI support. Online microgram schedules and treatment cycles are not validated prescribing standards.
How quickly does BPC-157 heal an ulcer?
No reliable human healing timeline exists. Symptom improvement cannot confirm that an ulcer has closed, that H. pylori has been eradicated, or that bleeding and recurrence risks are controlled.
Can BPC-157 be taken with a PPI, antibiotic, or other stomach medicine?
Interactions and combination safety have not been systematically established. Do not add BPC-157 to, or change, a prescribed ulcer or GI regimen without discussing the complete product and medication list with a qualified clinician.
Can BPC-157 replace a PPI or standard ulcer treatment?
No evidence supports using BPC-157 as a replacement. Standard care targets ulcer healing and the underlying cause, such as H. pylori or NSAID exposure. Delaying evaluated care can allow bleeding, perforation, obstruction, or another condition to go unrecognized.
What side effects can oral BPC-157 cause?
A reliable incidence profile has not been established. FDA concluded that clinical safety information was insufficient and noted product-quality risks involving identity, formulation, impurities, aggregation, microbial factors, and storage.
How is a stomach ulcer diagnosed?
Clinicians use symptoms and medical history together with appropriate testing. Depending on the case, that can include H. pylori breath or stool testing, blood tests, upper-GI endoscopy with biopsy, or imaging. Symptoms alone do not prove an ulcer.
When can ulcer symptoms be an emergency?
Seek urgent medical care for black or tarry stool, visible blood in stool, vomiting blood or coffee-ground material, sudden severe persistent abdominal pain, dizziness, fainting, rapid pulse, signs of shock, or rapidly worsening symptoms.
Primary and clinical sources
- U.S. FDA: 2026 briefing document for BPC-157-related bulk drug substances.
- U.S. FDA: July 2026 Pharmacy Compounding Advisory Committee meeting.
- U.S. FDA: bulk drug substances that may present significant safety risks.
- NIDDK: peptic-ulcer overview.
- NIDDK: peptic-ulcer symptoms and causes.
- NIDDK: peptic-ulcer diagnosis.
- NIDDK: peptic-ulcer treatment.
- American College of Gastroenterology: peptic-ulcer disease.
Review the exact product documentation
Explore the Mitovaryn BPC-157 page for its formulation, label, directions, warnings, and available testing information. Do not use a product page to self-diagnose an ulcer or replace evaluation and treatment for a GI condition.
Medical and regulatory disclaimer: This educational guide reflects sources reviewed in September 2026. It is not medical advice, a diagnosis, an ulcer-treatment plan, or a recommendation to purchase or use BPC-157. Evidence, product formulations, regulatory policies, and individual health circumstances can change. Seek care from a licensed healthcare professional for persistent or concerning GI symptoms and urgent care for possible bleeding, perforation, or shock.